Lonza Amaxa
德国Lonza Amaxa www.amaxa.com www.lonza.com.cn www.lonza.com
Amaxa公司成立于1998年,是德国一只处于快速发展中的生物技术团队,他们致力于一种高效率、非病毒基因转染技术——Nucleofector 的开发。在Nucleofector 技术和成功融资的基础上,Amaxa公司从最初的两个人迅速发展到现在的80多位技术人员的队伍,并迅速成为非病毒基因转染技术领域里最主要的公司之一。
Nucleofector 核酸转染仪 Nucleofector 核酸转染仪是将传统地电穿孔技术和专用地转染试剂结合起来的产物,针对不同的细胞类型,采用一套最理想的转染试剂和转染程序,以达到最理想的转染效率。Nucleofector 核酸转染仪特别适用于转染原代细胞和难以转染的细胞系,如T细胞及PC-12细胞系等。Nucleofector 技术是独一无二的,因为它可以直接将DNA转染到细胞核内,因此实现了因受到细胞分裂限制而一直困扰人们的原代细胞的高效率转染。在Nucleofector核酸转染仪的帮助下,您可以在肿瘤研究、免疫学、组织工程学及心血管疾病研究领域中轻而易举地获得大于90%的高效率基因转染率。
amaxa now a Lonza company
With the acquisition of amaxa, Lonza reinforces its position as a premium supplier to the cell discovery market with leading edge, proprietary technologies in the well defined market niches of transfection systems, which complement and expand the existing portfolio. These new products include the leading and unique Nucleofector® Technology, a transfection method which enables efficient and reproducible transfer of various substrates such as DNA, RNA or peptides into cells that are considered difficult or even impossible to transfect.
|